FDA’s Second-Guessing Of Device Applications Spurs Public Citizen Protest
This article was originally published in The Gray Sheet
Executive Summary
Public Citizen cites FDA's vacillations over Cyberonics' VNS Therapy as the source of its concern with the device as a possible treatment for depression
You may also be interested in...
Cyberonics Nabs Approval For Depression Device, Plans For Reimbursement
Cyberonics predicts reimbursement for VNS Therapy for treatment-resistant depression (TRD) will be fully secured by 2007, despite encountering protracted difficulties in gaining FDA approval
Cyberonics Nabs Approval For Depression Device, Plans For Reimbursement
Cyberonics predicts reimbursement for VNS Therapy for treatment-resistant depression (TRD) will be fully secured by 2007, despite encountering protracted difficulties in gaining FDA approval
Senate Finance Has No Jurisdiction Over VNS Approval – Cyberonics’ Cummins
An ongoing Senate Finance Committee inquiry into Cyberonics' February "approvable" letter will not hinder approval of VNS Therapy for treatment-resistant depression, CEO Skip Cummins asserted in a May 19 conference call